Placental protein 13 dilation of pregnant rat uterine vein is endothelium dependent and involves nitric oxide/calcium activated potassium channels signals

Mariacarmela, Gatto; Esposito, Milena; Gizurarson, Sveinbjörn; Henrion, Didier; Mandalà, Maurizio

doi:10.1016/j.placenta.2022.07.001

Cited by 3 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This aligns with PP13's role as a placental protein primarily involved in reproductive processes. Although prior studies demonstrated PP13 induced vasodilation in rat uterine arteries as well as in mesenteric arteries [19,20,28], this study is the first to examine PP13's effects on human uterine arteries, critical given that preeclampsia occurs exclusively in humans.…”

Section: Discussionmentioning

confidence: 92%

“…PP13 modulates several key processes critical for ensuring a successful pregnancy, including maternal immune responses to prevent maternal-fetal rejection [14], modulating oxidative stress and inflammation to mitigate oxidative damage and inflammatory responses [15,16], promoting cytotrophoblast invasion into the myometrium and ensuring spiral artery remodelling [17,18]. Animal studies have also shown promising results, demonstrating PP13's effect on modulating endothelial cell function [19,20], promoting angiogenesis and facilitating vascular remodeling necessary for proper placental and fetal development [21].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Placental Protein 13 (PP13): Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Gatto,

Esposito,

Morelli

et al. 2024

Preprint

View full text Add to dashboard Cite

Placental protein 13 (PP13) exhibits a plasma concentration that increases gradually during normal gestation, a process disrupted in preeclampsia, characterized by elevated vascular resistance, re-duced utero-placental blood flow and intrauterine growth restriction. This study investigated PP13’s role in vascular tone regulation and its molecular mechanisms. Uterine and subcutaneous arteries isolated from both pregnant and non-pregnant women were precontracted with the thromboxane analogue U46619, and exposed to PP13 using pressurized myography. The molecular mechanisms were further investigated using specific inhibitors for ni-tric oxide synthase (L-NAME+LNNA at 10-4 M) and guanylate cyclase (ODQ at 10-5 M). Results showed PP13 induced vasodilation in uterine arteries but not in subcutaneous arteries. Ad-ditionally, PP13 counteract U46619-induced vasoconstriction, which is particularly pronounced in pregnancy. Further investigation revealed that PP13's mechanism of action is dependent on activa-tion of the Nitric oxide-cGMP pathway. This study provides novel insights into the vasomodulatory effects of PP13 on human uterine ar-teries, underscoring its potential role in regulating utero-placental blood flow. These findings suggest PP13 may be a promising candidate for improving utero-placental blood flow in condi-tions such as preeclampsia. Further research and clinical studies are warranted to validate PP13's efficacy and safety as a therapeutic agent for managing preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Placental Protein 13 (PP13): Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Gatto,

Esposito,

Morelli

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…This mechanism may be due to the secretion of gal-13 into the intervillous space and perivenous area through the basal vein of the decidua, which forms gal-13 aggregates that attract and activate maternal immune cells and promote the transformation of trophoblast cells and small maternal spiral arteries [ 49 ]. PP13 induced uterine veins dilatation via the SKca–NO–BKca pathway in late pregnancy and became endothelium-dependent [ 146 ]. Researchers have proposed a gal-13 complementary therapy for the treatment of PE [ 89 ].…”

Section: Galectins In Pregnancy Disordersmentioning

confidence: 99%

Galectins: Important Regulators in Normal and Pathologic Pregnancies

Chen

Shi

Zheng

et al. 2022

IJMS

View full text Add to dashboard Cite

Galectins (Gal) are characterized by their affinity for galactoside structures on glycoconjugates. This relationship is mediated by carbohydrate recognition domains, which are multifunctional regulators of basic cellular biological processes with high structural similarity among family members. They participate in both innate and adaptive immune responses, as well as in reproductive immunology. Recently, the discovery that galectins are highly expressed at the maternal–fetal interface has garnerd the interest of experts in human reproduction. Galectins are involved in a variety of functions such as maternal–fetal immune tolerance, angiogenesis, trophoblast invasion and placental development and are considered to be important mediators of successful embryo implantation and during pregnancy. Dysregulation of these galectins is associated with abnormal and pathological pregnancies (e.g., preeclampsia, gestational diabetes mellitus, fetal growth restriction, preterm birth). Our work reviews the regulatory mechanisms of galectins in normal and pathological pregnancies and has implications for clinicians in the prevention, diagnosis and treatment of pregnancy-related diseases.

show abstract

Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Gatto,

Esposito,

Morelli

et al. 2024

IJMS

View full text Add to dashboard Cite

Placental protein 13 (PP13) exhibits a plasma concentration that increases gradually during normal gestation, a process that is disrupted in preeclampsia, which is characterized by elevated vascular resistance, reduced utero-placental blood flow, and intrauterine growth restriction. This study investigated PP13’s role in vascular tone regulation and its molecular mechanisms. Uterine and subcutaneous arteries, isolated from both pregnant and non-pregnant women, were precontracted with the thromboxane analogue U46619 and exposed to PP13 using pressurized myography. The molecular mechanisms were further investigated, using specific inhibitors for nitric oxide synthase (L-NAME+LNNA at 10−4 M) and guanylate cyclase (ODQ at 10−5 M). The results showed that PP13 induced vasodilation in uterine arteries, but not in subcutaneous arteries. Additionally, PP13 counteracted U46619-induced vasoconstriction, which is particularly pronounced in pregnancy. Further investigation revealed that PP13’s mechanism of action is dependent on the activation of the nitric oxide–cGMP pathway. This study provides novel insights into the vasomodulatory effects of PP13 on human uterine arteries, underscoring its potential role in regulating utero-placental blood flow. These findings suggest that PP13 may be a promising candidate for improving utero-placental blood flow in conditions such as preeclampsia. Further research and clinical studies are warranted to validate PP13’s efficacy and safety as a therapeutic agent for managing preeclampsia.

show abstract

Placental protein 13 dilation of pregnant rat uterine vein is endothelium dependent and involves nitric oxide/calcium activated potassium channels signals

Cited by 3 publications

References 43 publications

Placental Protein 13 (PP13): Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Placental Protein 13 (PP13): Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Galectins: Important Regulators in Normal and Pathologic Pregnancies

Placental Protein 13: Vasomodulatory Effects on Human Uterine Arteries and Potential Implications for Preeclampsia

Contact Info

Product

Resources

About